Drug Search Results
More Filters [+]

IMVT-1402

Alternative Names: IMVT-1402, IMVT1402, IMVT 1402
Latest Update: 2024-10-29
Latest Update Note: News Article

Product Description

Immunovant’s second investigational product, IMVT-1402, is also a novel, fully human FcRn-targeting antibody. As with batoclimab, in nonclinical studies, IMVT-1402 has been observed to reduce IgG antibody levels and is designed to enable a subcutaneous route of administration delivered in a matter of seconds. (Sourced from: https://www.immunovant.com/pipeline)

Mechanisms of Action: FcRn Blocker

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Roivant Sciences
Company Location: HAMILTON HM11 D0 HM11
Company CEO: Matthew Gline
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for IMVT-1402

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Autoimmune Disease Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events